Helmut Rainer Salih
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, Crysandt M, Jost E, Thol F, Heuser M, Götze K, Schlenk R, Salih H, Schittenhelm M, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kuendgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May A, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. Eur J Haematol 2024
13.10.2024Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
13.10.2024Eur J Haematol 2024
Bresser Helena, Schmoor Claudia, Grishina Olga, Pfeifer Dietmar, Thomas Johanna, Rehman Usama-Ur, Crysandt Martina, Jost Edgar, Thol Felicitas, Heuser Michael, Götze Katharina S, Schlenk Richard F, Salih Helmut Rainer, Schittenhelm Marcus, Heil Gerhard, Schwaenen Carsten, Müller-Tidow Carsten, Brugger Wolfram, Kuendgen Andrea, de Wit Maarten, Giagounidis Aristoteles, Scholl Sebastian, Neubauer Andreas, Krauter Jürgen, Bug Gesine, May Annette M, Wäsch Ralph, Duyster Justus, Döhner Konstanze, Ganser Arnold, Döhner Hartmut, Hackanson Björn, Becker Heiko, Lübbert Michael
TOF mass spectrometry-based immunopeptidomics refines tumor antigen identification.
Hoenisch Gravel N, Nelde A, Bauer J, Mühlenbruch L, Schroeder S, Neidert M, Scheid J, Lemke S, Dubbelaar M, Wacker M, Dengler A, Klein R, Mauz P, Löwenheim H, Hauri-Hohl M, Martin R, Hennenlotter J, Stenzl A, Heitmann J, Salih H, Rammensee H, Walz J. TOF mass spectrometry-based immunopeptidomics refines tumor antigen identification. Nat Commun 2023; 14:7472.
17.11.2023TOF mass spectrometry-based immunopeptidomics refines tumor antigen identification.
17.11.2023Nat Commun 2023; 14:7472
Hoenisch Gravel Naomi, Nelde Annika, Bauer Jens, Mühlenbruch Lena, Schroeder Sarah M, Neidert Marian Christoph, Scheid Jonas, Lemke Steffen, Dubbelaar MariLisa, Wacker Marcel, Dengler Anna, Klein Reinhild, Mauz Paul-Stefan, Löwenheim Hubert, Hauri-Hohl Mathias, Martin Roland, Hennenlotter Jörg, Stenzl Arnulf, Heitmann Jonas S, Salih Helmut Rainer, Rammensee Hans-Georg, Walz Juliane Sarah
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens
Backert L, Stevanovic S, Rammensee H, Weisel K, Kohlbacher O, Salih H, Kanz L, Niederwieser D, Vucinic V, Brümmendorf T, Schemionek M, Neidert M, Berlin C, Schuster H, Walz S, Kowalewski D, Walz J. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. Oncotarget 2017; 8:43915-43924.
04.07.2017A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens
04.07.2017Oncotarget 2017; 8:43915-43924
Backert Linus, Stevanovic Stefan, Rammensee Hans-Georg, Weisel Katja, Kohlbacher Oliver, Salih Helmut Rainer, Kanz Lothar, Niederwieser Dietger, Vucinic Vladan, Brümmendorf Tim H, Schemionek Mirle, Neidert Marian Christoph, Berlin Claudia, Schuster Heiko, Walz Simon, Kowalewski Daniel Johannes, Walz Juliane Sarah
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BMC cancer 2016; 16:25.
16.01.2016Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
16.01.2016BMC cancer 2016; 16:25
Kampa-Schittenhelm Kerstin, Salitzky Olaf, Akmut Figen, Illing Barbara, Kanz Lothar, Salih Helmut Rainer, Schittenhelm Marcus